Načítá se...
Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy
A major paradigm in cancer immunotherapy is to use checkpoint inhibitors to break regulatory mechanisms that usually guard the host against autoimmune diseases. CTLA-4-targeting immunotherapy was the first example that help to establish this paradigm. However, the clinically tested anti-CTLA-4 antib...
Uloženo v:
| Vydáno v: | Trends Pharmacol Sci |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210725/ https://ncbi.nlm.nih.gov/pubmed/31836191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tips.2019.11.003 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|